Sign in

    Amin (on for Maury Raycroft)

    Research Analyst at Jefferies

    Maury Raycroft is an Equity Research Analyst at Jefferies specializing in the biotechnology sector, with broad coverage that includes companies such as Cardiff Oncology, Affimed, BioCryst Pharma, Arrowhead Pharmaceuticals, and Mirati Therapeutics. Raycroft has issued more than 47 stock ratings, maintaining a success rate of approximately 21–40% and an average return per recommendation ranging from -14% to +3%, reflecting the inherent volatility and challenge in the biotechnology space. He began his career as a research analyst in the 2010s, joining Jefferies to provide in-depth coverage on emerging and established biotech firms; prior experience at other financial institutions has not been publicly disclosed. Raycroft holds professional analyst credentials and is likely registered with FINRA, with multiple years of experience generating both quantitative and qualitative insights for institutional investors.

    Amin (on for Maury Raycroft)'s questions to AFMD leadership

    Amin (on for Maury Raycroft)'s questions to AFMD leadership • Q3 2024

    Question

    Speaking on behalf of Maury Raycroft, he asked about the status and type of partnership discussions for AFM24 and whether the company was considering prioritizing its clinical programs, like AFM13 and AFM28, given its financial position.

    Answer

    The company stated they are evaluating all strategic partnership options for non-dilutive capital and are not focused on a specific deal type. Regarding prioritization, they are continuing to develop all three main clinical programs (AFM13, AFM24, AFM28) in parallel, as the data for each is compelling and warrants further investment.

    Ask Fintool Equity Research AI